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ABSTRACT 
BACKGROUND 
A viral load monitoring algorithm in the 2013 Western Cape Department of Health 
PMTCT guidelines include VL measurement in women who are antiretroviral (ART)-
experienced at presentation for antenatal care, the timing of subsequent VL 
measurements and criteria for regimen change. The study evaluates the 
implementation of the algorithm in women who are virologically nonsuppressed and 
determines the outcomes of  virological resuppression  and infant PCR status.  
METHODS 
This retrospective cohort study focused on all ART-experienced women who 
presented for antenatal care at one of two primary level Maternity Obstetric Units 
(MOUs) in Khayelitsha, Cape Town between July 2013 and June 2014. The study 
used routine data from facility registers, clinical records and electronic monitoring 
systems at the MOU, and referral ART sites and hospitals.. Data collected included 
age, ART clinic, start date and regimen, and maternal VL and infant PCR results. 
RESULTS 
Forty percent of the 1412 HIV-positive pregnant women, were ART-experienced, of 
whom 14.1% were VNS. Predictors of being VNS included a duration on ART of 
more than 4 years (p=0.04), attending an  ART clinic other than that in the facility 
(p=0.02),being on a second-line ART regimen (p=0.07) and being younger than 25 
years (p=0.05). The algorithm was correctly followed in up to 87.5% of women 
identified as VNS. The rate of virological resuppression by three months postpartum 
was 70.0% to 82.3%. Excluding three neonates who died, all of the 82.2% of infants 
tested were PCR negative. 
CONCLUSIONS 
Nearly 15% of ART-experienced women were virologically nonsuppressed on 
presentation for antenatal care.  
Levels of adherence to the guideline, and virological resuppression rates of up to 
82.3% are encouraging.  
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The implementation of the VLM algorithm could be improved by the integration of 
obstetric and ART care, the adoption of a single electronic monitoring system and 
the use of standardised integrated clinical stationery.  (300 words) 
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PART 1:  STUDY PROTOCOL 
INTRODUCTION 
Over the past two decades, great progress has been made globally in programmes 
aimed at the prevention of transmission of HIV from mother-to-child (PMTCT).  In the 
days preceding any form of PMTCT intervention, mother-to-child transmission 
(MTCT) of HIV was estimated to be 15-30% by the time of delivery, with subsequent 
breastfeeding adding a further 20% risk (Newell, 2005).  By the late 2000’s, in well-
resourced countries, transmission rates of less than 2% were achieved  through the 
combined approach of antiretroviral prophylaxis, elective caesarean section and the 
avoidance of breastfeeding (Newell, 2005). By December 2009, the global coverage 
of PMTCT services reached 53%, while many low-and-middle income countries had 
achieved at least 80% coverage.  These include high HIV-burden countries such as 
Botswana, Namibia, Swaziland and South Africa (UNAIDS, 2011).  However, 
developing countries face enormous challenges in implementation of optimal PMTCT 
programmes due to  various factors,  including limited resources, struggling health 
systems, high HIV prevalence, and socio-behavioural practices. 
The risk of MTCT is influenced by a number of factors, including the woman’s viral 
load (VL) and immune status, as well as obstetric practices (Kourtis, 2010). Of these 
factors, the VL is the strongest predictor of transmission (Thorne et al, 2004). A 
higher baseline VL in the mother is associated with vertical transmission to the infant 
(Garcia, 1999). It is also associated with a longer duration to virological suppression 
on antiretroviral treatment (ART) (European Collaboration, 2007) and suboptimal 
virological suppression at the time of delivery (Louis, 2005). Evidence from Cape 
Town, South Africa suggests that almost half the ART-naïve women in this setting 
presented  with VLs that could be considered high (greater than 10 000 copies/ml)  
(Myer et al, abstract CROI 2014).  
Suboptimal adherence to ART is the strongest predictor of poor viral suppression in 
PMTCT, as is the case in general ART programmes (Louis, 2005).  There are 
numerous barriers to good ART adherence; these include those related to health 
services access and organisation, the complexity of the regimen, pill burden and 
adverse events associated with the medication, an individual’s lack of education, 
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forgetfulness, depression or other illness, and community attitudes of stigma, 
discrimination with consequent  lack of disclosure (World Health Organisation 
Consolidated Guidelines, 2013).  Lack of partner involvement and suboptimal or 
fewer antenatal care visits have also been identified as risk factors for poor 
adherence in PMTCT programmes (Columbini et al., 2014). 
Late antenatal presentation results in a shorter duration on ART and consequently 
poorer virological suppression by the time of delivery (Louis, 2005).  Women who 
present for antenatal care late in pregnancy or arrive in labour having had no 
antenatal care at all, are thus at highest risk of transmission.  This scenario is 
particularly prevalent in resource-poor countries, but even in well-resourced settings, 
approximately one third of women may not have suppressed at the time of delivery 
(Louis, 2005; European Collaboration, 2007). 
Ideally, frequent VL monitoring during pregnancy could alert clinicians to women 
whose VLs are detectable, and make it possible to intervene in order to achieve 
virological suppression. In 2013, the World Health Organisation (WHO) 
recommended viral load monitoring (VLM) as the preferred approach to diagnose 
and confirm ART failure (WHO Consolidated Guidelines, 2013). These guidelines 
propose testing VL at six months post ART initiation. However, no distinction is made 
between VL monitoring in pregnancy as opposed to in routine ART programmes. 
Given the generalised nature of these recommendations, and the fact that late entry 
into antenatal care is so common, the majority of pregnant women would be unlikely 
to have a six month VL test before delivery.   
In many resource-constrained countries, the high costs of VL testing have meant that 
VLM is not routine in either general ART programmes, or in PMTCT services.  Well-
resourced countries can afford to test more intensively. The United States of 
America’s National Institute of Health  guidelines of May 2014 propose that a VL be 
measured  in all HIV-infected pregnant women at their initial antenatal visit, and 
several times thereafter during the pregnancy (Panel on Treatment of HIV-Infected 
Pregnant Women and Prevention of Perinatal Transmission, 2011).  
The 2014 British HIV Association guidelines go a step further in proposing HIV 
resistance testing before initiation of ART in pregnant women. No such VL 
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monitoring policies could be found in the literature for poorly-resourced countries, 
suggesting no guidelines exist for monitoring VL in pregnant women in such settings  
Where guidelines regarding VL monitoring in pregnancy exist, they have focused on 
women who initiate ART for the first time in pregnancy. Yet, with improved ART 
coverage over time, increasing numbers of women enrolling in antenatal care are 
ART-experienced. A study in Gugulethu, Cape Town, found that nearly 25% of ART-
experienced women are not virologically suppressed on presentation to the antenatal 
services (Myer et al., 2014).  Case reports in Khayelitsha, Cape Town, found that 
several babies testing positive on Polymerase Chain Reaction (PCR) at six weeks 
had been born to women who had claimed to be taking ART at other sites when 
entering antenatal care, but had suboptimal adherence or had in fact defaulted 
treatment (Giddy, personal communication, May 2014).  Hence there is a missed 
opportunity for PMTCT through neglecting to actively ascertain the viral status of 
ART-experienced women, and manage them accordingly.  
One of the objectives of South Africa’s National Strategic Plan for HIV/AIDS/STIs for 
2011-2016 is to reduce the transmission of HIV from mother-to-child to less than 2% 
at six weeks by 2011 and less than 5% by 18 months of age by 2016.  As a strategy 
to achieve this, in March 2013, the South African Department of Health adopted the 
Option B of the WHO Consolidated Guidelines (2013), whereby all HIV-positive 
pregnant and breastfeeding women are eligible for ART; after cessation of 
breastfeeding, those women who do not qualify for ART under standard criteria stop 
this treatment.  
The Western Cape Health Department decided to implement Option B+ whereby all 
of these women would remain on lifelong ART. Included in these guidelines is a VL 
monitoring algorithm that had been drafted by concerned Khayelitsha clinicians in 
conjunction with local HIV experts. To address the missed opportunities for the 
optimal management of HIV-infected pregnant women who are not virologically 
suppressed, the guidelines recommend more frequent testing of VL in pregnancy, 
including a baseline VL in ART-experienced women (Appendix 1).  The algorithm 
was implemented in Khayelitsha antenatal services in May 2013. 
As discussed above, while policies for VL monitoring in pregnancy exist in some 
well-resourced countries, no evidence of similar policies in resource-poor countries 
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could be found in the literature. There is thus a gap in what is known about VL 
monitoring in pregnancy in resource-constrained settings such as South Africa.   
The aim of this research is to describe the implementation of the Western Cape VLM 
algorithm and to evaluate its effectiveness in identifying ART-experienced pregnant 
women with detectable viral loads and achieving improved outcomes in their 
virological suppression antenatally and up to 12 weeks postnatally. In addition, the 
PCR status of their infants at six weeks will be assessed. 
AIM 
The aim of the study is to evaluate the implementation of viral load monitoring 
guidelines in ART-experienced HIV-positive pregnant women and determine the 
outcomes of these interventions on the virological status of the women and PCR 
status of their infants.  
OBJECTIVES: 
The objectives of the study are for the cohort of ART-experienced HIV-positive 
women presenting for PMTCT antenatal care at Site B Midwife Obstetric Unit (MOU) 
in Khayelitsha, during the 12 month period from July 2013 to June 2014:  
1. To describe the implementation of the Western Cape HIV viral load 
monitoring algorithm as regards VL testing and actions taken in response 
to ART-experienced women being found to have a detectable VL on 
presenting for antenatal care; 
2. For those ART-experienced women who had a detectable VL on 
presenting for antenatal care : to determine the virological outcomes at 
their last monitoring visit; 
3. To determine whether there are factors associated with non-suppression 
of  VL in these women; and 
4. To determine the proportion of exposed infants born to ART-experienced 
women who had a detectable VL on presenting for antenatal care, who are 
diagnosed HIV-positive by a PCR test at six weeks. 
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RESEARCH QUESTIONS: 
 The research questions are: 
1. What are the socio-demographic characteristics and clinical features of 
ART-experienced HIV-positive pregnant women presenting for PMTCT 
antenatal care? 
2. What is the virological status of ART-experienced HIV-positive women 
accessing PMTCT antenatal care? 
3. To what extent are the guidelines implemented in the management of 
ART-experienced woman having a detectable VL on presenting for 
antenatal care? 
4. What are the virological outcomes of ART-experienced women who have 
a detectable VL on presenting for antenatal care, at their last monitoring 
visit (antenatally or up to 12 weeks postpartum)? 
5. Are there significant risk factors associated with a detectable VL in this 
cohort of ART-experienced HIV positive women accessing antenatal 
PMTCT care?  
6. What are the outcomes of PCR testing at six weeks of the infants of ART-
experienced women who had a detectable VL on presenting for antenatal 
care? 
METHODS 
SETTING: 
Khayelitsha is a peri-urban settlement 40kms from the Cape Town city centre, which 
is home to approximately 450 000 people (Statistics South Africa, 2012). There are 
high levels of poverty in the population, with an unemployment rate approaching 
40% in 2011. Over half of the population live in informal housing.  
The population of Khayelitsha experiences a triple burden of disease: infectious 
diseases (predominantly HIV and tuberculosis), chronic diseases of lifestyle and 
trauma. The antenatal HIV positivity rate rose from 19.3% in 2000 to 37% in 2011 
(Provincial Government of the Western Cape, 2012). By the end of March 2014, 
routine statistics report that 28738 clients were receiving ART in Khayelitsha heath 
facilities.  
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PMTCT services have been provided in Khayelitsha since 1999. Over time, 
regimens have become more efficacious, progressing from AZT-only (1999), ART for 
eligible women (2004) to the current ART for life for all pregnant and breastfeeding 
women (Option B+) (Stinson et al., 2014)  
The Khayelitsha Site B MOU is one of two facilities providing primary level antenatal 
and delivery services to women in Khayelitsha. Routine data estimate that an 
average of 350 women present for antenatal care at Site B MOU monthly, of whom a 
third are HIV-positive. Up to 40% of HIV-positive women report being on ART at their 
first antenatal visit. Since the introduction of Option B+ in July 2013, the number of 
pregnant women initiating ART at the facility has doubled: from an average of 40 
(January to June 2013) to an average of 80 per month (July 2013 to February 2014).  
These women are initiated on ART almost exclusively by professional nurses. 
Half of these women who present are obstetrically ‘low risk’ and deliver at the facility. 
Those who have obstetric risk factors or complications during delivery are referred 
antenatally or during labour to either the Khayelitsha District hospital four kms away, 
or to the tertiary-level Tygerberg hospital almost 30 kms away, depending on the 
degree of risk. Approximately 50 of the HIV-exposed infants are followed up at the 
adjacent Site B Community Health Centre (CHC) while the remainder present at 
other clinics in Khayelitsha or further afield.   The majority of the Site B CHC babies 
are PCR-tested at six weeks. Routine service data shows that in the seven months 
since the introduction of Option B+ in July 2013, only one of the more than 250 
babies tested at the facility tested PCR positive. 
STUDY POPULATION 
The study population will be the cohort of all ART-experienced HIV-positive pregnant 
women presenting for antenatal PMTCT care at the Site B Midwife Obstetric unit 
(MOU) in Khayelitsha during the period July 1 2013 to June 30 2014. Parts of the 
analysis focused on a sub-sample of ART-experienced women who have a 
detectable viral load when presenting for antenatal care. All of the latter cohort are 
included in the sample, regardless of whether they only had one antenatal visit, their 
pregnancy was terminated or they were lost to follow-up. 
STUDY DESIGN 
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This will be a quantitative study that focuses on a retrospective cohort. The 
characteristics of the cohort and their virological outcomes will be described.  Actions 
taken by health care providers in response to women with a detectable VL at 
enrolment into antenatal care will be presented, and an assessment will be made as 
to whether these actions were consistent with the those specified in the VL 
monitoring algorithm. An analytic component will consider a detectable viral load on 
testing at enrolment into antenatal care as an outcome of interest, and determine 
whether there are associated significant risk factors for a detectable viral load, and 
predictors of virological non-suppression. 
DATA MANAGEMENT AND ANALYSIS 
Data will be extracted from the following sources: 
1. Paper registers: the Site B MOU HIV Counselling and Testing (HCT) and 
labour ward registers (including the PMTCT labour ward register); PMTCT 
Baby registers in Khayeltisha clinics. 
2. Electronic ART registers:  eKapa (Site B MOU and 3 other Khayelitsha 
facilities) and TIER.Net (remainder of Khayelitsha facilities), with linkage to 
laboratory results. 
3. Patient folders at Site B MOU and other Khayelitsha facilities, where data 
are found to be incomplete on the electronic record. 
Extracted data will be recorded in hard copy extraction forms (Appendix 2) by the 
researcher and/or assistant before being captured into an Access data-base for 
analysis.   Data will be independently checked for errors of transcription or 
translation. Statistical analysis will be performed using Stata version 12 (StataCorp, 
Texas, USA, 2012).  
PROTECTION OF PRIVACY OF DATA  
Hard copies of extracted data will be kept, using codes to link patient identifiers to 
patient-specific information. The codes will be accessible to only the researcher and 
research assistant. 
The software data-base will be encrypted and stored on the researcher’s laptop, 
which is also password-protected.  
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SITE PREPARATION PLAN 
The researcher is an employee of the Provincial Government of the Western Cape 
(PGWC) Health Department with responsibility for monitoring of HIV services in the 
Khayelitsha subdistrict, and therefore has an existing relationship with the facility and 
its management. Once ethical approval and health authority permission has been 
granted, the researcher will meet with substructure and facility staff to present the 
proposed study. A brief pilot will be undertaken to gain insight into the service 
structure and to determine potential challenges to data collection.  
ETHICAL CONSIDERATION AND HIGH LEVEL APPROVAL  
Ethical approval has been sought from the Faculty of Health Sciences Human 
Research Ethics Committee of the University of Cape Town, under an existing 
protocol which covers routine cohort monitoring and research in the HIV care 
services within Khayelitsha  (HREC Ref: 2005/395: ‘Enhanced routine surveillance of 
an HIV clinic population  in Khayelitsha’). While this protocol has existing approval 
from local authorities, study-specific approval will be sought from both the Health 
Department of PGWC, and the City of Cape Town Health Department. 
The proposed study will be guided by the ethical principles stated in the Declaration 
of Helsinki which was developed by the World Medical Association (World Medical 
Association, 2012). 
There is a potential risk of breach of confidentiality due to the accessing of patient 
identifiers while seeking eligible women for the study from the routine data sources. 
However, given the complexity of working across paper and electronic platforms, the 
cross-checking of data using names and folder numbers is unavoidable in order to 
ensure data quality. The researcher acknowledges that this procedure may have 
ethical implications in terms of protecting patient confidentiality through the use of 
data collection which is not anonymous. However, it is argued that using patient 
names in programme research is not a new phenomenon. Once extracted, 
confidentiality of patient information will be maintained by the use of codes for 
personal identifiers, and password-protection of computers used. Records with 
personal identifiers will be destroyed once data cleaning is complete. No other 
potential harm to the patient cohort is envisaged. 
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The study results will be communicated to the health management of both the 
PGWC and City of Cape Town, as well as to staff of the facilities involved in the 
study. While no direct benefit to the patients in the cohort is anticipated, it is hoped 
that the study results will contribute to optimising the VL monitoring algorithm which 
can be operationalised through appropriate standard operating procedures, thus 
providing benefit to pregnant women going forward. Training of staff in the 
implementation of the algorithm could be conducted. It is anticipated that the findings 
of this research may have wider applicability, and publication of findings in journals 
or presentation at conferences will be sought. 
BUDGET 
Costs of travel, stationery, printing and photocopying will be paid for by the 
researcher. The research assistant will be paid for related work by the Centre for 
Infectious Diseases Epidemiology and Research at the University of Cape Town. 
There will be no other funding sources. 
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PART 2: LITERATURE REVIEW 
BACKGROUND TO PMTCT:  PROGRESS, ACHIEVEMENTS AND CHALLENGES: 
Over the past two decades, significant progress has been made globally in 
programmes for the prevention of mother-to-child transmission (PMTCT) of HIV. In 
the absence of any preventive interventions, transmission rates of 15-20% occur by 
delivery, with prolonged breastfeeding potentially doubling this transmission risk 
(Newell, 2005). Over this period, our knowledge and understanding of the 
transmission of HIV from mother-to-child (MTCT) has increased significantly, which 
has enabled the development of increasingly effective policy and prevention 
guidelines for PMTCT programmes globally.  This has been accompanied by efforts 
to expand and strengthen maternal and HIV services in developing country settings. 
There has been impressive programme implementation scale-up in many countries. 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) reported that by 
December 2009, global coverage of PMTCT services had reached 53%, while many 
low-and-middle income countries had achieved at least 80% coverage (UNAIDS, 
2011). While coverage in Africa has been variable, several high HIV-burden 
countries, such as Botswana, Namibia, Swaziland and South Africa are amongst 
those having achieved this target (Govender & Coovadia, 2014). Due to these 
combined strategies, transmission rates of 14-42% (Kourtis & Bulterys, 2014) have 
been reduced to 1-2% in developed countries, and even in some resource-limited 
settings (Ramkissoon & Coovadia, 2014).   
In 2011, UNAIDS released ‘Countdown to Zero: a Global Plan for the elimination of 
new HIV infections among children by 2015 and keeping their mothers alive’. The 
plan advocates a comprehensive four-pronged approach to eliminating MTCT. In 
addition to conventional PMTCT interventions, there should be a focus on primary 
prevention of HIV in women, prevention of unwanted pregnancies in HIV-infected 
women, and care and support for the HIV positive mother, her partner and children 
(UNAIDS, 2011). This strategy is in keeping with the Millenium Development Goals 
(MDG) four and five, which aim to reduce maternal and child mortality (MDG Africa 
Steering Group, 2008).  
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 In 2013, the World Health Organisation (WHO, 2013) issued Consolidated 
Guidelines that recommended the adoption of Option B for PMTCT whereby all HIV-
positive pregnant women qualify for antiretroviral therapy (ART) for the duration of 
pregnancy and breastfeeding, and Option B+, which recommended lifelong ART for 
these women.   
Given these progressive guidelines and successes, recent UNAIDS and WHO plans 
set elimination of MTCT (eMTCT) targets of a 90% reduction in new paediatric 
infections, a transmission rate of less than 5%, and a 50% reduction in HIV-related 
maternal deaths. The case of the Mississippi baby who was started on ART within 
hours of her birth in 2010, and in whom no HIV virus was detected after cessation of 
ART, made eMTCT look within reach (Persuad et al., 2013). Unfortunately, the 
Mississippi baby experienced HIV viral rebound in 2014 (McNeil, 2014). Other 
interventions to test eMTCT are currently being explored.  
The first public sector PMTCT programme in South Africa was started in 1999 by the 
Western Cape Department of Health (DOH) in partnership with Medecins Sans 
Frontieres (MSF) (Stinson et al., 2014). Following this, South Africa’s National 
PMTCT programme was launched in a phased approach from the early 2000s. By 
2010, 95% of South Africa’s health facilities were providing PMTCT services, more 
than 98% of women were tested, and 91.7% were receiving either ART or dual 
prophylaxis (Ramkissoon & Coovadia, 2014). The percentage of pregnant women on 
triple ART rose from 33.1% to 46.2% between 2010 and 2011 (Bhardwaj et al., 
2014), before the adoption of WHO PMTCT Option B in 2013. The increasing 
PMTCT programme coverage in South Africa is reflected in the impressive decrease 
in MTCT rates. Transmission rates of 32% were reported in the early 1990’s 
(Ramkissoon & Coovadia, 2014).  A review of South African national laboratory data 
revealed that HIV infection rates in infants tested fell from 16.4% in 2006 to 2.4% in 
2012, after the adoption of more comprehensive PMTCT interventions (Sherman et 
al., 2014). By 2012, 73% of exposed infants were estimated to have had a 
Polymerase Chain Reaction (PCR) test at six weeks. Between 2008 and 2012, the 
number of infants diagnosed with HIV dropped from 8405 to 4557 (Sherman et al., 
2014). 
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However, developing countries continue to face enormous challenges in the 
implementation of optimal PMTCT programmes, due to a number of factors, 
including limited resources and struggling health systems, often in the context of high 
HIV prevalence. The UNAIDS Global Plan (UNAIDS, 2011) identifies and prioritises 
many of these challenges, arguing for strong leadership, sufficient financial 
investment, up-to-date strategic planning at a national level, greater allocation of 
human resources for health and strengthening of access to essential supplies. It 
acknowledges the need to address broad socio-cultural impediments.  
Even in well-functioning programmes, achieving eMTCT would require the closing of 
numerous programme gaps. Chief amongst these is the attrition cascade, which 
sees significant losses to care at every step from initial HIV testing of the mother to 
ART initiation of an infected infant, and ongoing ART care for both mother and child 
(Pennazzato et al., 2014). There are several significant missed opportunities for 
PMTCT. These include the failure to identify HIV-positive pregnant women who enter 
antenatal care and who should initiate ART (Bhardwaj et al., 2014) and the 
identification and management of poor ART adherence in women who either initiate 
ART in pregnancy or are ART-experienced when enrolling for antenatal care. These 
poorly adherent or defaulting women are at high risk of MTCT, yet there is a dearth 
of appropriate interventions to mitigate this risk.  The targeted use of viral load 
testing would assist in identifying these women in need of increased adherence 
support and specific clinical management. 
RISK FACTORS FOR MTCT 
HIV MTCT can occur during pregnancy, labour and delivery or postpartum during 
breastfeeding through transfer of virus in maternal blood, breastmilk and other 
maternal bodily fluids (Newell, 1998). It has been estimated that in a non-
breastfeeding population, approximately two thirds of vertical transmission occurs 
during labour and delivery (Newell, 1998). Breastfeeding can increase the 
transmission rate by 15% to 14-42% depending on the duration (Kourtis, 2010). 
Numerous risk factors for MTCT have been identified, of which maternal HIV viral 
load (VL) is the strongest (Newell, 2005) Transmission risk is associated with the 
level of the viral load (Garcia, 1999; Kourtis, 2010), as well as the stage of disease 
and immunological compromise (Newell, 2005). Other risk factors include invasive 
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obstetric procedures, such as foetal scalp monitoring and artificial rupture of 
membranes (Kourtis, 2010; Garcia, 1999). Lower infant birthweight and prematurity 
have been postulated as risk factors for MTCT (Newell, 2005). 
INTERVENTIONS TO REDUCE MTCT 
Interventions to reduce MTCT have addressed the identified risk factors, and have 
included the mother’s use of ART to reduce maternal VL, ART as post-exposure 
prophylaxis (PEP) for infants, and obstetric procedures that minimise opportunities 
for MTCT.  
The PACTG 076 trial of 1991-1993 established the principles of reducing vertical 
transmission of HIV to infants through the use of ART antenatally to pregnant women 
and postnatally to infants (Connor et al., 1994). The trial demonstrated a relative 
reduction of 67.5% in MTCT at six weeks in non-breastfeeding women through the 
use of Zidovudine (AZT) from 14 weeks of pregnancy through delivery, and AZT as 
PEP to the infant. Many subsequent studies have evaluated the administration of 
ART in various drug combinations and for differing durations, provided to the mother 
and/or the infant in breastfeeding and non-breastfeeding women; these trials are 
summarised in the 2011 Cochrane review (Siegfried et al., 2011). In breastfeeding 
populations, MTCT could be reduced to less than 5% by extended use of maternal 
ART and the adoption of safer breastfeeding practices, including exclusive 
breastfeeding (Kuhn et al., 2013; Tsague & Abrahams, 2014). 
Based on the findings of these trials, PMTCT protocols progressed from the use of a 
single dose of one antiretroviral drug to mother and infant, to progressively more 
complex and efficacious regimens whereby triple therapy was provided for those 
women with more serious disease, and dual therapy for others. The current WHO 
2013 Consolidated HIV guidelines recommend ART for all pregnant and 
breastfeeding women (Option B or B+) and prophylaxis for infants based on 
transmission risk and feeding method. 
The risk of MTCT is related to the level of the maternal viral load (Garcia et al., 
1999). PMTCT outcomes are thus optimised by achieving viral suppression as early 
as possible before birth, which is the time of the highest transmission risk (Mnyani et 
al., 2014).  Time to virological suppression is influenced by a number of factors, the 
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strongest being the efficacy of the specific ART regimen adopted (The European 
Collaborative study, 2007). The Collaboration (2007) found that the median time to 
viral suppression in a subgroup of women on a specific regimen could be as short as 
five weeks. Louis (2005) demonstrated the positive association between the baseline 
viral load of the pregnant or breastfeeding woman and time to viral suppression. 
Women who were more immunologically compromised took longer to suppress their 
viral load (Garcia et al., 1999). Duration on ART is an independent predictor of 
transmission risk (Fitzgerald et al., 2014). The lowest rates (0.5% and 0.16%) are 
achieved in those women taking ART before pregnancy and who are adherent 
(Cooper et al., 2002). Fitzgerald et al. (2014) found that transmission risk was 
reduced by 20% for each additional week of ART. However, Hoffman et al. (2010) 
found only an 8% reduction per week. In a recent study in Zambia, Chibwesha et al. 
(2011) concluded that at least 13 weeks of ART predelivery was required for 
maximal efficacy. 
While the earliest possible initiation of ART in pregnancy would maximise the 
likelihood of achieving viral suppression, public policy has been challenged by 
factors including resource constraints and concerns about the teratogenicity of 
certain antiretroviral drugs,  such as Efavirenz (Ford et al., 2011), in the first 
trimester. In recent years, the recommended time of ART initiation in pregnancy has 
become progressively earlier.  
Evidence accumulated from the abovementioned studies culminated in the WHO 
2013 Consolidated HIV Guidelines recommending either Option B or B+ for PMTCT. 
This policy was adopted by Malawi in 2011. A number of other resource-constrained 
countries have subsequently followed suit, including South Africa, in 2013 (Kieffer et 
al., 2014). It is estimated that with implementation of WHO Option B/B+, peripartum 
MTCT rates of 2% can be achieved, with breastfeeding adding 0.2% per month to 
this transmission rate (Ramkissoon & Coovadia, 2014).  
The implementation of guidelines is compromised by the reality of patients’ health 
seeking behaviours and existing health systems. In many countries, including South 
Africa, significant numbers of women present for care at advanced stages of 
gestation,  or attend few antenatal visits, or do not access antenatal care at all and 
attend in labour for the first time.  System delays in, or failure to initiate ART 
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commonly occur (Fitzgerald et al., 2014). Such realities have a deleterious effect on 
maternal and child outcomes by reducing the duration of maternal ART received. 
ADHERENCE TO TREATMENT AND CARE 
Adherence to ART is essential to achieve virological suppression. Barriers to 
adherence in PMTCT programmes in Sub-Saharan Africa have been well 
summarised in two recent literature reviews (Gourlay et al., 2013; Columbini et al., 
2014) and in the WHO 2013 Consolidated Guidelines.  
Adherence can be compromised by factors relating to the medication itself: 
unpleasant or serious drug toxicities, complexity of regimens, pill burden and dietary 
restrictions (WHO, 2013). The increasing use of drug formulations with better side-
effect profiles, and once-daily fixed dose combination of ART are attempts to 
address these barriers. 
Adherence risk factors at the level of the individual woman include young age 
(Gourlay et al., 2013; Columbini et al., 2014), substance abuse, depression and 
other illness (WHO, 2013). At a societal level, adherence is negatively affected by 
ongoing stigma towards and discrimination against HIV-infected individuals. The 
resultant fear of disclosure and it’s possible consequences deprives many women of 
the support of partners and family, factors that improve adherence (Gourlay et al., 
2013; Columbini et al., 2014). 
The health system itself poses numerous barriers to health care visits and 
medication-related challenges to adherence. These include the accessibility of the 
service and the related direct and indirect costs of clinic attendance (Columbini et al., 
2014; WHO, 2013), system challenges, such as staff and equipment shortages 
(Gourlay et al., 2014), drug stock-outs, and the necessity for frequent visits and long 
waiting times (WHO, 2013). Sub-optimal staff-client interactions can have a negative 
effect on adherence (Columbini et al., 2014). These include negative staff attitudes in 
general, as well as a lack of trust in staff, fears of breaches of confidentiality, and 
discrimination by staff.  The uptake of PMTCT interventions and adherence is 
negatively affected by poor quality of counselling and too little emphasis on the 
importance of adherence (Gourlay et al., 2013). Continuity of care, and linkages 
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between antenatal and other primary care services are important in promoting 
adherence. 
Much has been written recently regarding the benefits to PMTCT uptake and 
adherence of the involvement of a male partner in antenatal and postnatal care. 
Such involvement can be promoted by supporting disclosure, providing couples’ 
counselling and testing, and encouraging male partners to accompany women on 
visits to the clinic (Peltzer et al., 2011; Osoti et al., 2014; van den Berg et al., 2015)  
VIRAL LOAD MONITORING 
While routine monitoring of HIV VL has been a key component of ART programmes 
in developed countries from the outset (United States of America Public Health 
Service Task Force, 2004; de Ruiter et al., 2008), until recently this has not been the 
case in many resource-constrained countries. A Ugandan study (Essajee & 
Kumarasamy, 2014) concluded that VL monitoring was less cost-effective than other 
forms of monitoring because of relatively low clinical benefit and relatively high cost. 
Essajee and Kumarasamy (2014) argue that these constraints have resulted in the 
prioritisation of rapid scale up of ART initiation. In such contexts, VL monitoring has 
been regarded as optional, but not a prerequisite for the rollout of treatment 
programmes.  
The purpose of VL monitoring of patients on ART is important at both the individual 
and public health level. For the individual patient, the purpose is to improve clinical 
outcomes. In a systematic review, Tucker et al. (2014) make the case that VL 
monitoring has the potential to assess early response and adherence to ART, and to 
create the opportunity for interventions to achieve viral suppression through 
adherence support. This view is supported by a study in Swaziland in which 
Jobanputra et al. (2014) found that the main impact of VL monitoring was on 
reinforcing adherence. Essajee and Kumarasamy (2014) argued that the absence of 
VL monitoring results in a delayed diagnosis of treatment failure and the 
accumulation of resistant mutations which result from delays in switching ART, while 
Tucker et al. (2014) add that viral load monitoring reduces the likelihood of 
unwarranted switching, thus preserving future treatment options for the patient.  
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In the absence of virological testing, reliance has been placed on defined clinical 
and/or immunological (CD4 count) monitoring. A number of studies have, however, 
highlighted that criteria such as these have a poor positive predictive value. Tucker 
et al. (2014) conclude that the combination of clinical and immunological monitoring 
has significant benefit in morbidity and mortality endpoints compared with clinical 
monitoring alone. However, a survival benefit of VL over CD4 count monitoring was 
not consistently demonstrated; an observational study by Keiser showed benefit, 
while a randomised control trial by Merriman did not (Tucker et al., 2014).  
From a public health perspective, monitoring allows for programme surveillance. 
However, it is particularly important in the preservation of first line regimens by 
avoiding the accumulation of resistant mutations at the population level. In 2007 
Boulle and Ford suggested that at the start of programme roll-out in developing 
countries, viral load monitoring was not initially necessary; virological outcomes were 
likely to be good, given the low levels of transmitted resistance in these countries 
and the strong focus on the promotion of adherence. However, the authors 
proceeded to argue that this situation had changed as the programmes had 
expanded, and high-level genotypic resistance was being demonstrated.  
For all these reasons, pressure has mounted for the implementation of virological 
monitoring even in resource-constrained settings.  In 2009, the WHO made a 
recommendation for the use of VL monitoring in ART programmes to confirm 
treatment failure (WHO, 2009). In 2010 it was recommended that VL be assessed 
routinely at six monthly intervals, with a VL greater than 5000 being defined as 
failure and an indication to switch to a second line regimen (Nelson et al., 2014). 
Finally, in June 2013, the WHO issued a strong recommendation that VL monitoring 
be adopted as ‘the preferred monitoring approach to diagnosis, and confirming ART 
failure’ (WHO, 2013). VL should be measured after six months on treatment and 
annually thereafter; the threshold for the diagnosis of treatment failure was lowered 
to 1000. CD4 count and clinical monitoring could be maintained in situations where 
this gold standard was not available. The WHO conceded that there was only weak 
evidence to support the recommendation, as Tucker et al. (2014) demonstrated in 
their systematic review. 
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Nelson (2014) reports that when  the 2013 guidelines were issued, 54% of 69 Low 
and Middle Income Countries indicated that they had already adopted routine VL 
monitoring, a further 40% monitored in a targeted fashion, while in only 6% of these 
countries, VL monitoring was not available at all. South Africa included routine VL 
monitoring from inception of the ART programme in 2004.  
There are significant challenges to the implementation of WHO guidelines. In many 
resource-constrained countries, financial resources have to be available, laboratory 
infrastructure and equipment secured, adequate and appropriately skilled staff 
available, supply chain management improved, and health systems strengthened in 
several other respects.  
A number of strategies are proposed to finance virological monitoring. The decrease 
in drug costs, especially that of second line drugs has the potential to allow the 
reallocation of resources to virological monitoring. Stevens and Ford (2014) propose 
the use of CD4 testing at baseline for initial clinical management, and the reduction 
of CD4 count monitoring thereafter in those who demonstrate VL suppression. These 
authors argue that resources should be channelled to both VL and drug resistance 
testing. Other options include batching of testing and negotiating reduced rates for 
high volumes of testing: these strategies have been adopted in South Africa. The 
decentralisation and simplification of virological testing, as has been done for infant 
Dried Blood Spot PCR testing, has the potential to decrease costs and reduce the 
dependence on laboratories and highly skilled staff. As Essajee and Kumaramsany 
(2014) argue, there is an urgent need for newer more sensitive, consistent and 
reliable Point of Care viral load assays; such techniques are under development 
(Stevens et al., 2014; Scott et al., 2015)  
VIRAL LOAD MONITORING IN PREGNANCY  
Given that VL is the greatest risk factor for MTCT, a strong argument is made for 
more frequent VL monitoring during pregnancy and breastfeeding.  In well-resourced 
countries, frequent VL monitoring during pregnancy has been standard practice for 
more than ten years (British HIV Association, 2012; Panel on Treatment of HIV-
Infected Pregnant Women and Prevention of Perinatal Transmission, 2014). 
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However, the 2013 WHO guidelines do not make a distinction between VL 
monitoring in pregnancy as opposed to routine ART programmes. Given that many 
women in developing countries, enrol late for antenatal care and thus many HIV 
positive women initiate ART in advanced pregnancy, following routine guidelines, a 
significant number of these women would deliver before their first VL test at six 
months.  Similarly, pregnant women who conceive while on ART might not qualify for 
their annual VL test screening during their pregnancy. 
As ART coverage increases, a greater proportion of women enrolling in antenatal 
care are ART-experienced. In a Cape Town study, 35% of women enrolling in 
antenatal care were already on ART (Myer et al., 2014). ART-experienced pregnant 
women have previously been assumed to be virally suppressed during their 
pregnancy. However, Myer et al. (2014) reported that 24% of ART-experienced 
women in a public sector clinic were not virologically suppressed at the time of 
presenting for antenatal care;  13% of these women had a VL>1000. These women 
may have defaulted ART entirely, have been poorly adherent to ART, or have 
experienced virological failure due to transmitted or acquired resistance to ART.  
Case reports in Khayelitsha, Cape Town, found that several babies testing HIV 
positive at six weeks had mothers who had claimed to be taking ART at other sites 
when entering antenatal care, but had in fact either defaulted treatment, or had 
suboptimal adherence (Ibeto et al., 2014). These authors conclude that ‘the absence 
of routine viral load monitoring at antenatal booking and subsequently through 
pregnancy and breastfeeding, resulted in a failure to detect women who had 
defaulted ART prior to or during pregnancy’ (Ibeto et al., 2014:108). 
There is no clear international policy for VL monitoring in pregnancy. As there is 
limited time during pregnancy in which to achieve viral suppression and prevent 
MTCT, it is extremely important to timeously identify high VLs in women newly 
initiated on ART, as well as those who are ART-experienced. This provides an 
opportunity to achieve virological suppression before delivery through intensified 
adherence support, restarting ART in those who have defaulted, and switching of 
ART regimens in cases of failure. In addition, virological monitoring facilitates the 
identification of infants at high risk of in-utero transmission. The South African 
National Consolidated HIV guidelines (National Department of Health, 2014) 
recommend that these ‘high risk’ infants are tested for HIV at birth, and that those 
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testing positive should be initiated on ART immediately. Maternal virological 
monitoring also has the potential to influence decisions regarding infant feeding and 
prophylaxis.   
POLICIES FOR THE MONITORING OF HIV VIRAL LOAD DURING PREGNANCY  
In well-resourced countries, intensive VL monitoring of HIV positive pregnant women 
on ART is promoted. The 2014 guidelines of the USA National Institute of Health 
(NIH) recommend that VL is measured in all HIV-infected pregnant women at their 
initial antenatal visit, and if it is high, monthly until they are suppressed, and three-
monthly thereafter (Panel on Treatment of HIV-Infected Pregnant Women and 
Prevention of Perinatal Transmission, 2014).  The 2014 guidelines of the British HIV 
Association go a step further in proposing HIV resistance testing before initiation of 
ART in pregnant women (BHIVA, 2014). Given that until recently, VL monitoring has 
not been routine in general ART or PMTCT programmes in most resource-
constrained countries, it is not surprising that VL monitoring policies and guidelines 
for these countries could not be found in the literature. Where VL monitoring has 
occurred in pregnancy, it has followed the VL monitoring policies of general ART 
programmes, and thus mainly focused on women initiating ART in pregnancy. There 
are thus missed opportunities for preventing transmission by not ascertaining the 
virological status of women initiated on ART during pregnancy, as well as ART-
experienced women, and to intervene if necessary to achieve viral suppression.  
In 2011 the South African National Department of Health (DOH) produced a National 
Strategic Plan for HIV/AIDS/STIs (NSP) for 2012-2016 (National Department of 
Health, 2011). One of the Plan’s objectives is by 2016 to reduce MTCT to less than 
2% at six weeks postpartum and to less than 5% by 18 months of age.  As a strategy 
to achieve this, in March 2013, the National DOH adopted the WHO’s PMTCT 
Option B. 
The Western Cape DOH implemented Option B+ in July 2013. These guidelines for 
the first time in South Africa made specific recommendations for VL monitoring 
during pregnancy and breastfeeding (Department of Health Western Cape. 2013). 
The VL monitoring guidelines were presented in the form of an algorithm (Appendix 
A). More frequent VL measurement in pregnancy and breastfeeding was 
recommended.  It was advised that women initiated on ART should have a VL test at 
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four months, or earlier (36 weeks) if they were likely to deliver before four months on 
ART. ART-experienced women should be tested at first antenatal visit if no recent 
result were available. In women who were virologically suppressed, VL monitoring 
should be done six-monthly for the duration of pregnancy and breastfeeding; 
thereafter monitoring should revert to the standard annual VL monitoring of the 
general ART programme. Where women were not virologically suppressed, further 
interventions (retesting or switching of regimen) were guided by the number of VLs 
that were unsuppressed, and whether the gestational age of the pregnancy was 
before or after the third trimester. This algorithm was implemented in Khayelitsha 
antenatal services on 1 July 2013, with initial support by local MSF clinicians. The 
Western Cape DOH modified the algorithm in 2014, and a 2015 update is awaited.  
The National DOH has for the first time included a VL monitoring algorithm in their 
2015 guidelines (National Department of Health, 2014). 
NEED FOR THIS RESEARCH 
There has finally been an acceptance in the South African public health sector of the 
need for a policy on VL monitoring during pregnancy and breastfeeding. The 
implementation of the 2013 Western Cape VL monitoring guideline has not yet been 
evaluated. There is a need to establish whether the guideline was successfully 
implemented and what implementation challenges there were. It is important to 
establish whether the guideline was effective in ensuring that pregnant women with 
high VLs were identified timeously and were provided with the appropriate 
adherence support, care and treatment to maximise their chance of viral 
resuppression, and hence minimise the risk of MTCT.  
This research aims to fill this gap as far as the antenatal period is concerned.  The 
research focuses on women who are ART-experienced at the time of their first 
antenatal visit. Currently little is known about these women in the South African 
public health system.  
The findings of this study will improve understanding of the challenges in the 
implementation of the guidelines, and enhance efforts to improve this. It will provide 
a profile of pregnant women with previous ART experience, particularly those who 
are not virologically suppressed when entering into antenatal care.  
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The results of the study could contribute to the future refinement of VL monitoring 
guidelines for pregnant and breastfeeding HIV positive women in South Africa. 
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PART 3: MANUSCRIPT 
INTRODUCTION 
BACKGROUND  
Great progress has been made globally over the past two decades in reducing 
vertical transmission of HIV. This is the result of implementing evidence-based 
Prevention of Mother-to-Child Transmission (PMTCT) programmes. The most recent 
recommendations are the World Health Organization (WHO)’s Option B/B+ [1] which 
advise antiretroviral therapy (ART) for all HIV-positive pregnant and breastfeeding 
women. In addition, global coverage and scale-up of PMTCT programmes reached 
53% by 2010 [2], with several low and middle-income countries, including South 
Africa, having reached the target of 80%. PMTCT interventions have resulted in the 
reduction of mother-to-child transmission (MTCT) rates of 14-42% [3] without any 
form of intervention, to 1-2% in developed countries, and even in some resource-
limited settings [4]. The Joint United Nations Programme (UNAIDS) report [2] refers 
to the elimination of MTCT, setting targets of transmission rates of less than 5%, and 
a 90% reduction in paediatric HIV infections by 2015, and it reiterates that 
programme gaps need to be addressed in order to achieve these targets.  
HIV viral load (VL) is the strongest predictor of MTCT [5].  Frequent VL monitoring 
(VLM) in pregnancy facilitates the early detection of poor adherence to ART [6], 
creating the opportunity for interventions to urgently support adherence in order to 
achieve viral suppression. VLM further enables the timeous detection of treatment 
failure, and consequent regimen change [7].  
In a context of increasing levels of resistance to ART medication [7], in its 2013 
guidelines [1], the WHO recommends routine annual VLM as ‘the preferred approach 
for the detection of treatment failure’. Until recently, VLM has not been widely 
implemented in resource-constrained settings, even in general ART programmes [8]. 
Many health systems  are struggling and under-resourced: VL monitoring may thus 
not be implemented due to the high costs of VL testing, shortages of technically 
skilled staff,  and poor infrastructure, transport and supply chain management to  
support this intervention. [9] 
42 
 
A number of strategies are being employed to overcome the challenges faced by 
these countries. These include the freeing up of resources for VLM by decreases in 
the cost of drugs, especially second line ARVs [9] and the phasing out of long-term 
CD4 testing [10].  The challenges of poor infrastructure and transport, and 
inadequate numbers of technically-skilled staff could be addressed by the 
decentralisation of testing, which will be possible in the near future by simplification 
of the technical process of VL testing, including point of care testing [10]. 
Given the urgency of achieving viral suppression in pregnancy, VL should be 
monitored more frequently than annually, which is the guideline followed in most 
ART programmes. While PMTCT guidelines for enhanced VLM have existed in 
developed countries for many years [11, 12] no such guidelines could be identified 
for resource-constrained settings at the time of this study. In June 2013, the Western 
Cape Department of Health issued PMTCT guidelines [13] based on WHO Option 
B+ [1]. These guidelines include a VLM algorithm for both ART-naïve and ART-
experienced pregnant women which appears in Appendix A. The aim of the 
algorithm was to reduce MTCT by more frequent monitoring of pregnant and 
breastfeeding women on ART, in order to identify those who are not virologically 
suppressed, and to achieve virological re-suppression as soon as possible, through 
increased adherence support and clinical interventions. Little is known of the 
effectiveness of the implementation of these guidelines, nor is there descriptive 
evidence regarding the profile of women who could benefit from their 
implementation.  
This study focused on the cohort of women who were ART-experienced but 
virologically non-suppressed when presenting for antenatal care. The purpose of the 
study was to evaluate to what extent the VLM algorithm was followed in these 
women, and determine their virological status at their last monitoring visit, as well as 
the PCR status of their infants. The study also aimed to describe the 
sociodemographic characteristics and clinical features of the cohort, and to 
determine whether there were factors associated with viral non-suppression in these 
women.  
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SETTING 
Khayelitsha, a township 30 km from the Cape Town city centre, is home to 
approximately 450 000 people [14], the majority of whom live in poverty and are 
unemployed. In 2011, the HIV prevalence in Khayelitsha in 2012 was 34.3% [15]. 
Antenatal and delivery services for low-risk pregnancies are provided at two primary-
level nurse-managed Midwife Obstetric Units (MOUs). Routine data estimates that 
50% of women who access antenatal care in Khayelitsha deliver at these two 
facilities. Women with obstetric risk factors or complications are referred to district or 
tertiary-level hospitals. ART services are provided at all of the 11 primary level clinics 
and the 2 MOUs in Khayelitsha. Traditionally, most women who became pregnant 
while attending these ART services, continued to attend these services while 
attending an MOU for obstetric care. Since the implementation of Option B+ in the 
Western Cape on 1 July 2013, all HIV-positive ART-naïve women accessing 
obstetric care at a Khayelitsha MOU initiate ART and receive integrated HIV and 
obstetric care by professional nurses there. Women identified at either of these 
MOUs as having a non-suppressed VL have been encouraged to transfer their ART 
care to the MOU, so that urgent case management could be provided. Post-delivery, 
all mothers and their infants are referred for ongoing care to a clinic of their choice. 
Site B MOU in Khayelitsha was chosen as the site for the study as an existing study 
on PMTCT Option B+ was already underway at the facility and a degree of overlap in 
the studies was planned. Routine data for 2013/14 estimate that 320 women enrolled 
in antenatal care, and 150 delivered per month at this MOU. While the majority of 
these women reside in Khayelitsha, some live in other parts of Cape Town, while 
others relocate temporarily from a neighbouring province to access obstetric services 
in the metropolitan area.  
Patient data across the pregnancy and ART service continuum of the Western Cape 
are recorded on standardised HIV stationery and captured into one of three 
electronic monitoring platforms in accordance with local data monitoring protocols. 
Given that the three monitoring platforms are not linked, electronic follow up of 
patients across obstetric and ART services is limited. Furthermore, electronic ART 
data is not collected on ART-experienced women in the MOU unless they transfer 
their ART care to the MOU. Hospitals record patient information by electronically 
44 
 
scanning patient notes. However these records cannot be accessed from clinics.  
Pregnancy and delivery information is recorded in a patient-held maternity record, 
which is filed at the delivery site 
THE VIRAL LOAD MONITORING ALGORITHM 
The elements of the guidelines pertaining to ART-experienced pregnant women 
stipulated that VL testing be done at the time of presenting for antenatal care 
(‘booking’) for all women who had been on ART for more than four months unless a 
VL result within this time period could be found. In the algorithm women were 
classified as VS (virologically suppressed, VL <= 400 copies/ml) or VNS (virologically 
non-suppressed, VL> 400 copies/ml) based on their VL at the time of booking.  All 
women identified as VNS should have received increased adherence support. Their 
further clinical management was guided by their gestational age at booking and their 
ART regimen. Women on a first line ART regimen who booked before the third 
trimester needed to have their VLs repeated after two months, and be switched to a 
second line ART regimen should they still be VNS. However, women on first line who 
booked in the third trimester should have had Alluvia (a protease inhibitor) added to 
their regimen, and been switched to a second line ART regimen if still VNS after 
three months: this was likely to be post-delivery. In cases where the woman’s VL 
was non-suppressed for the second consecutive time, she should have been 
changed to a second line regimen without delay. VNS women already on a second 
line regimen at booking should have received adherence support and repeat VL 
testing; infant post-exposure prophylaxis and feeding method would need to be 
discussed.  
In this study, three important pre-delivery elements of the algorithm were traced in 
each ART-experienced VNS woman: the identification of ART-experienced women 
through measurement of VL at booking, the repeating of VL testing at two months, 
and the switching of regimens if indicated. Outcomes of maternal VL and infant’s HIV 
status on Polymerase Chain Reaction (PCR) testing were established.  
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METHODS  
STUDY POPULATION 
The study population included all HIV-positive women enrolling for antenatal care at 
one Khayelitsha MOU over 12 months from the implementation of the Option B+ 
guidelines on 1 July 2013 to 30 June 2014. Specifically, the study design comprised 
a retrospective cohort of ART-experienced women; for VNS women follow-up and 
outcomes data were traced until January 2015. Much of the analysis focused on a 
sub-sample of ART-experienced women who have a detectable viral load when 
presenting for antenatal care. Data on all these VNS women was analysed 
regardless of whether they only had one antenatal visit, their pregnancy miscarried 
or was terminated, or the women were lost to follow-up. 
DATA COLLECTION 
The facility staff kept a VL/CD4 register designed specifically to trace HIV-positive 
women at their first visit and to identify those eligible for management as specified in 
the VL algorithm. Clinical data included CD4 count and VL testing of ART-
experienced pregnant women. The register was used to assist in tracking of VL 
results and to facilitate the recall of women with high VLs. ART-experienced women 
were identified from the VL/CD4 register; when the use of this register ceased at the 
end of May 2014, the relevant column in the HIV testing (HCT) register fulfilled this 
purpose. For the subset of VNS women, the following data was collected: age, ART 
regimens at initiation, booking and delivery, duration on ART, ART clinics attended, 
CD4 and VL results, obstetric details (gravidity, parity, gestational age at booking, 
pregnancy outcome and delivery site) and maternal virological outcomes and infant 
PCR results. This information was collected by reviews of their MOU folders, and 
missing information obtained through electronic data sources, the National Health 
Laboratory Service (NHLS) patient data-bases, and manual audits of patient records 
at relevant clinics, district and tertiary hospitals. For VS women, a subset of this data 
(age, ART regimens, duration on ART, and ART clinics attended), were sought 
through searches of the NHLS data-base and electronic monitoring systems. All 
information was recorded on a paper tool. 
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In addition to support data collection efforts, the MOU folders of 37 of the VNS 
women were reviewed to document potential gaps in clinical recordkeeping and data 
regarding the management of these women. Triangulation of data from the HCT, 
CD4/VL and electronic registers was undertaken in a related study to assess gaps 
that might exist in the identification of the VNS women. 
DATA CAPTURING AND ANALYSIS 
Information on the ART-experienced women was electronically captured from the 
paper tool. The relevant data was analysed using Stata Version 13 (Statacorp, 
Texas). Continuous data were analysed using a two-sample t-test or Wilcoxon rank-
sum. Categorical data were analysed using the χ2 (chi-square) statistic and logistic 
regression. Multiple logistic regression was used to model the predictors of being 
virologically non-suppressed. Forward stepwise procedures were used in model 
selection, with the Akaike Information Criterion being used to assess best model fit.  
These same data was used to construct an ART and obstetric flow-chart history for 
each of the VNS women. From these histories it was possible to determine whether 
the key elements of the algorithm for each VNS woman had been followed, and what 
the maternal virological and infant PCR status outcomes were in each case. By 
manually collating the individual compliance and outcomes, overall measures were 
obtained for the cohort.  
. 
ETHICS APPROVAL 
Ethics approval was granted by the Human Research Ethics Committee at the 
University of Cape Town. In addition, the Western Cape Department of Health 
granted permission for access to the site for data collection.  
RESULTS  
DESCRIPTION OF THE ART-EXPERIENCED COHORT 
A total of 1412 pregnant HIV-positive women were identified as having enrolled in 
antenatal care during the study period (Figure 1). Of these 848 (60.0%) initiated ART 
at the MOU according to Option B+ guidelines and 564 (40.0%) were ART-
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experienced.  Of the ART-experienced women, VL results were not found for 82 
(14.5%). Of the remaining 482 women, 414 (85.9%) were found to be VS and 68 
(14.1%) were VNS. 
Twelve women disclosed at first antenatal visit that they had stopped taking ART; 
their VL was thus not measured and they were thus not initially identified from the 
VL/CD4 register as they had no VL entered. Data analysis was at an advanced stage 
when this was discovered; for this reason they were excluded from the 53 VNS 
women investigated. A further 30 (3 VNS and 27 VS) who did not appear in the 
VL/CD4 register had been identified in a related study, and were excluded as they 
too were identified too late in the data collection process. Of those with VL results, 
data for 93.5% (n=387/414) of VS women and 77.9% (n=53/68) of VNS women were 
analysed. These 440 women represent 78 % (n= 440) of the full cohort of 564.  
CHARACTERISTICS  OF VS AND VNS PREGNANT WOMEN 
VS and VNS ART-experienced women were compared by age, duration on ART and 
ART regimen at first antenatal visit, and the most recent ART clinic attended (Table 
1). This data was complete for VNS women, while for VS women there was data for 
age, ART regimen, duration on ART and recent ART clinic in 94.1%, 82.7%, 82.2% 
and 82.4% respectively. No significant difference was shown in mean age of the VS 
and VNS women (32 years vs 31 years, p=0.17) or for median duration on ART (31 
months (IQR 18, 50) vs 37 months (IQR 19, 63), p=0.23). However, the ART 
regimen at booking and recent ART clinic attended approached significance (p=0.07 
and p=0.06 respectively). 
LOGISTIC REGRESSION MODEL OF PREDICTORS OF ART-EXPERIENCED 
PREGNANT WOMEN BEING VIROLOGICALLY NON-SUPPRESSED 
A logistic regression model for predicting VNS was derived; the best model included 
all four variables (Table 2).  Exploratory bivariate data analysis guided the 
categorisation of the data.  
Women attending a clinic other than that in the same facility as the MOU were 2.2 
times more likely to be VNS (p=0.02). Women on ART for four or more years were 
2.1 times more likely to be VNS than those on treatment for fewer than four years 
(p=0.04). Women 30 or more years old were 70% less likely to be VNS than women 
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younger than 25 (p=0.05). However, there were only 26 women in the latter group. 
Women on a second line ART regimen at booking were 2.3 times more likely to be 
VNS than those on first line but the p value fell just short of significance (p=0.08) 
ART ADHERENCE 
Case histories collated from a number of sources suggest factors that could either 
put women at risk of poor adherence or reflect poor adherence in the past (Figure 2). 
Twenty two (42%) of the 53 VNS women had attended more than one ART clinic 
and/or had attended a clinic outside Khayelitsha. This is consistent with the results of 
the logistic regression. A history of defaulting and restarting ART was established in 
38% (n=20/53) of VNS women. While seven of the 53 VNS women (13.2%) were 
already on a second line regimen at booking, a further 32.1% (n=17/53) had 
previously had an indication to switch regimens but this switch had not occurred. 
Forty two percent (n=22/53) of the VNS women could not be traced postpartum, 
either electronically or through the NHLS. 
CLINICAL CHARACTERISTICS OF VNS PREGNANT WOMEN 
Clinical 
The results of the most recent pre-booking CD4 counts were retrieved for 92.5% 
(n=49/53) of the VNS women, and ranged between 34 - 641 cells/µL, with a median 
of 252 cells/µL (IQR 170, 338 cells/µL) (Table 3a).  
The median VL of the 53 women at first antenatal visit was 3929 (log 3) (IQR 898, 
49119). Fourteen of the 53 women (26.4%) had VLs < log 3, which could have 
constituted a transient elevation of VL (‘viral blip’). Nineteen of the 53 women 
(35.8%) with VLs log 4 or greater were likely to have defaulted ART entirely, while 20 
(37.7%) with intermediate VLs could have either had poor adherence, or have been 
failing ART due to viral resistance; the remaining 14 (26.4%) may have experienced 
a transient ‘viral blip’. By adding the 12 declared defaulters to the 19 presumed 
defaulters, 45.6% of the women known to be VNS (n=31/68) could be estimated to 
have defaulted ART entirely: this gives a default rate of 6.4% (n=31/482) of the ART-
experienced women. When presented with their booking VL result, nine of the 53 
women were recorded as having admitted to defaulting from or adhering poorly to 
their ART.  
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Comparing recent CD4 counts with booking VL results, 16.3% (n=8/49) of the 
women with CD4 count results had a CD4 count less than 100 cells/µL, five of whom 
had VLs ≥ log 5 (Table 3b). Again, it is likely that these women had completely 
defaulted their ART, but did not report this at their first antenatal visit.  Five of the 49 
women (10.2%) had CD4 counts ≥ 500, three of whom had a VL less than 1000 (log 
3). 
Obstetric characteristics 
The gestational age at first antenatal visit was established for 49 (92.5%) of the VNS 
women.  The median gestational age at booking was 19 weeks (IQR 16, 27; range 6, 
35). While 14.3% (n=7/49) booked before 12 weeks, the majority (71.4%, n=35/49) 
of women booked in the second trimester (Table 4). Of the seven who booked in the 
third trimester, two were already 35 weeks pregnant. 
Of the 49 VNS women for whom there was gravidity data, (22.4%, n=11/49) were 
primigravid. Almost half the women (48.9%, n=24/49) had a gravidity of two or three 
while 28.5% (n=14/49) were gravida four or five.  
Excluding the five pregnancies that either miscarried or were terminated, the delivery 
site for  93.8% (n=45/48) of the women was identified. Thirty three percent (n=15/45) 
of VNS women delivered at the MOU. The remainder delivered at the district hospital 
(28.9%, n=13/45) or the tertiary hospital (33.3%, n=15/45).  
IMPLEMENTATION OF THE VL MONITORING ALGORITHM 
Of the 564 women identified as ART-experienced, 482 (84.5%) could be classified 
as virologically suppressed (VS) / non-suppressed (VNS) based on a VL measured 
at first antenatal visit.   
Of the 53 VNS pregnant women, repeat predelivery VLs were indicated in 40 
(75.5%), of which 34 (85%) were measured. On the basis of these results, a change 
to a second line regimen was indicated for 15 women: 73.3% (n=11/15) had their 
regimen changed. Thus 40% of the VNS women (n=18/53) were on a 2nd line 
regimen by delivery. 
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Of the 53 women identified as VNS who were included in the study, the guidelines 
were followed in 79.2% (n=42/53) of cases. Excluding those who lost their 
pregnancies, this increases to 87.5% (n=42/48).  
Compliance with the algorithm could also be estimated through modelling scenarios 
using the   gaps in the care cascade demonstrated in this study.  For example, were 
100 VNS women to present for antenatal care before 28 weeks and remain in care, 
and those identified as VNS all required a regimen change after a second non-
suppressed VL, only 53 of the women would have been managed according to the 
VLM algorithm.  
OUTCOMES OF IMPLEMENTING THE VL MONITORING ALGORITHM 
Nineteen women (55.9%, n=19/34) were VS on repeat predelivery VL testing; a 
further four achieved viral resuppression before delivery after a regimen change 
(Figure 3). Thus 67.6% (n=23/34) of the women were known to be VS predelivery. A 
further five women became VS within three months of delivery. Hence a total of 
82.3% (n=28/34) of the women were known to have virologically resuppressed by 
three months postpartum. If, however, one calculates the results using as a 
denominator the 40 women for whom predelivery VLs were indicated, and assuming 
a worst case scenario in which those six women who did not have a repeat VL did 
not virologically resuppress, these figures fall to 47.5% (n=19/40) pre regimen 
change, 57.5% (n=23/40) pre-delivery and 70% (n=28/41) by 3 months postpartum. 
Of the six women who were not retested, two were not suppressed when they 
booked for their next pregnancy less than a year later  
Of the five women who should have had regimen changes, four were still VNS by 
two months 
In summary, depending on assumptions made, predelivery virological resuppression 
rates could range from 57.5% to 67.6% and rates at 3 months postpartum from 70% 
to 82.3%. 
There were 48 live births (Table 4). Four infants had birth PCRs measured as 
specified in the 2013 Western Cape PMTCT guidelines [13]; all these tests were 
negative. Of the 45 infants who survived beyond the neonatal period, 82.2% 
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(n=37/45) had PCRs performed at approximately six weeks, and a further 6.7% 
(n=3/45) between four and six months.  All these PCRs were negative. Six week 
PCR results could not be found for three of the four babies who had birth PCRs.  
 
A REVIEW OF FILING, DATA MONITORING SYSTEMS AND CLINICAL 
RECORDKEEPING  
A number of challenges were encountered in data collection for this study; these are 
reported as they are likely to have negatively impacted on the implementation of the 
VLM algorithm.  
Despite there having been recent efforts to reorganise the filing system, 14.3% 
(n=9/63) of the folders originally sought for the study could not be found.  
There were challenges in accessing patient data electronically for this study due to 
the use in Cape Town of multiple electronic monitoring systems, which limit the 
sharing of clinical information between the MOU and ART services in feeder clinics 
and hospitals. Staff at the MOU are unable to access ART records for women who 
receive ART care at services using a different electronic monitoring platform. Unless 
women transfer their care to the MOU, their clinical details are not electronically 
captured at the MOU, and cannot be entered onto other monitoring systems. Thus 
other sites cannot determine electronically details of test results and other 
management ART-experienced women receive at the MOU.  
A comparison of the different manual and electronic registers used for HIV positive 
women revealed a number of inconsistencies, which compromised identification of 
the study cohort. In several cases, incorrect HIV status was recorded in the HCT 
(HIV Counselling and Testing) register:  women recorded as HIV negative, HIV 
positive (newly diagnosed) or HIV positive ‘not on ART’ were found to either be/have 
been on ART at another clinic, or to have been initiated on ART at the MOU. There 
were also inconsistencies between the HCT and CD4/VL registers: some women 
recorded as HIV positive in the HCT register did not appear in the VL/CD4 register, 
while others recorded as HIV negative in the HCT register did.  
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Thirty five ART-experienced women were misclassified as ART-naive in the VL/CD4 
register, while 20 were not entered at all. In the last months of the study period, few 
results were entered in the VL/CD4 register. The results of 27 women appearing in 
the register could not be found on the NHLS data-base. Use of the register ceased in 
the last six weeks of the study period. 
As a check of other electronic monitoring systems in the Cape Town area could not 
be done at the time, these findings might underestimate the extent to which ART-
experienced women are not identified for care.  
Limited clinical data could be obtained from many of the patients’ folders. A manual 
review of 37 folders of VNS women (Table 5) found ten (27%) with maternal case 
records filed. Fifteen (40.5%) folders had no VL result filed or recorded in clinical 
notes. Only 15 (40.5%) of clinical notes made reference to adherence support. A 
minority of folders had clinical notes recording the need to repeat a VL or to change 
regimen; most of these notes were written by the medical officer from Medecins 
Sans Frontiers (MSF) who was supporting the implementation of the VLM guidelines. 
DISCUSSION 
This study evaluated the extent and outcomes of the implementation of an algorithm 
for the monitoring of viral loads in 1412 HIV positive pregnant women at a primary 
care antenatal and delivery site in Khayelitsha, Cape Town, with a specific focus on 
53 ART-experienced women who were virologically non-suppressed (VNS) at 
presentation for antenatal care. Forty percent of the HIV positive cohort 
(n=564/1412) were ART-experienced, of whom 14.1% (n=68/482) were virologically 
non-suppressed at their first antenatal visit. Many women were severely 
immunocompromised. There were high rates of hospital delivery and poor pregnancy 
outcomes. 
Significant predictors of virological non-suppression included a younger age (< 25 
years), a longer duration since ART initiation (> 4 years) and attending an ART clinic 
other than that in the same facility as the antenatal and delivery service, while being 
on a second-line ART regimen at presentation approached significance. While the 
virological status of nearly 13% of women could not be determined, the guidelines 
were correctly followed in 79.2%-87.5% of women classified as virologically non-
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suppressed. Predelivery and 3 month postpartum virological resuppression rates 
ranged from 57.5% to 67.6% and 70.0% to 82.3% respectively. Excluding three early 
neonatal deaths, 82% of the infants had PCR tests at approximately 6 weeks, all of 
which were negative.    
THE COHORT OF ART-EXPERIENCED PREGNANT WOMEN 
A large proportion (40%) of HIV positive women have ART-experience when 
presenting for antenatal care at the study site: this is very similar to the 35% found in 
a study by Myer et al in an adjacent township [16].  This may reflect the 
comparatively good ART coverage in the Khayelitsha subdistrict, the increasing 
numbers of women qualifying for ART under the general or PMTCT programme 
and/or an active desire of ART-experienced women to start or add to their family. It 
would be instructive to determine what proportion of these pregnancies were 
unplanned. 
ADHERENCE AND DEFAULTING IN THE ART-EXPERIENCED PREGNANT WOMEN 
The proportion of ART-experienced women who were VNS at presentation for 
antenatal care (14.1%) is very similar to the 13% found in the same Myer study [16]. 
The estimated defaulter rate of 6.4% (n=31/482) in this cohort of ART-experienced 
pregnant women cannot be directly compared to that of the general ART population 
in Khayelitsha as the loss-to-follow up rates in the latter programme are reported by 
year of initiation, and include unreported deaths and ‘silent’ transfers out. 
These high rates of defaulting, poor ART adherence and possible treatment failure 
amongst these ART-experienced women are of grave concern, particularly given that 
risks of perinatal transmission of HIV – even a resistant virus – to their infants, and 
the threat to their own health. It is imperative that the reasons for these behaviours in 
the local context be explored and understood, so that appropriate and effective 
interventions can be implemented.  
Systematic reviews by Colombini [18] and Gourlay [19] report a wide range of factors 
that could contribute to poor adherence and retention in care: the factors may relate 
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to the individual client, the society in which they live, the health system and the ART 
medication prescribed.  
The predictors of virological non-suppression derived in this study are all plausible as 
factors that could affect adherence or retention in care, and concur with the findings 
of many studies reported in the latter reviews. The lower levels of virological 
suppression in women younger than 25 years compared to those 30 years or older is 
consistent with several studies that report youth as a risk factor for poor adherence 
[18,19]. 
The significantly inferior virological suppression in women who initiated ART more 
than four years previously could reflect the increasing risk of developing viral 
resistance over time, especially in those with suboptimal adherence. It may also 
result from treatment fatigue [20], leading to poor adherence or defaulting from ART 
entirely. 
Being on a second line ART regimen at booking as a predictor of being VNS could 
be explained by a poor adherence history prior to this pregnancy that resulted in a 
regimen change: such poor adherence may have continued on the second line 
regimen. It may also be related to the high pill burden and intolerability of the second 
line ART regimen: these factors could be additive. 
The study showed that women who received prepregnancy ART at the ART clinic in 
the same facility as the antenatal service were less likely to be virologically non-
suppressed than those attending any other ART clinic. There could be several 
reasons for this. The clinic is regarded by many as a centre of excellence; MSF 
initiated ART services in the facility in 2001 and have made an ongoing contribution 
to the development of clinical skills and health systems strengthening in the 
Khayelitsha district, particularly at this clinic. Several innovations aimed at improving 
adherence and virological resuppression have been piloted at this facility with good 
outcomes. In addition, the HIV activist organisation, the Treatment Action Campaign, 
has a strong presence at the clinic: the treatment literacy delivered by their peer 
educators could have contributed to better rates of virological suppression in the 
patients attending the clinic.  
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This finding may also reflect the fact that women who received their pre-pregnancy 
ART elsewhere are in some respect different. It is possible that these women had 
defaulted ART at their original clinic due to various challenges, but were reluctant to 
return to the same facility for antenatal care as they feared the reaction of clinic staff: 
poor staff attitude has been reported as a risk factor for poor adherence [18]. These 
could be women who have relocated to Khayelitsha and not transferred their care to 
a local clinic. There may be women whose adherence had been compromised by 
leading unsettled lives involving relocation or movement within Cape Town, or 
between Cape Town and other regions or provinces, notably the Eastern Cape. This 
is suggested by the case histories obtained which found that almost half the VNS 
women had attended more than one clinic and/or had attended a clinic outside 
Khayelitsha. According to a Khayelitsha clinician [21], patients report that, especially 
in the rural areas of the Eastern Cape, they struggle to access due to factors such as 
limited ART services, difficulty in accessing ART clinics due to long distance and 
limited transport, a reluctance of clinic staff to accept patients from other areas 
without referral, and ART stock-outs.  
Other commonly reported challenges to adherence [18, 19] could apply in the local 
context: these include social stigma and discrimination, and denial or non-disclosure 
of status. The latter may account for the incorrect information given to staff by some 
women in this study. Poor knowledge of HIV/ART and the importance of PMTCT 
could also contribute. According to the same clinician [21] there are increasing 
anecdotal reports of ART patients stopping ART treatment for a variety of reasons, 
including the belief that they are well and no longer require ART, or are cured of HIV. 
OBSTETRIC CHARACTERISTICS OF THE VIROLOGICALLY NON-SUPPRESSED 
PREGNANT WOMEN  
Routine delivery data at the study site [17] reports that 50% of women who enrol for 
antenatal care at the facility deliver there. In contrast, fewer than 40% of the VNS 
women delivered at this facility, and a third of them at tertiary level. This is likely to 
reflect complications due to the severe immunosuppression reported for many of the 
women. Certainly the mother who is thought to have died had been admitted to the 
tertiary hospital with septicaemia and related complications. 
IMPLEMENTATION OF THE VLM ALGORITHM 
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For the 53 VNS women in the study, there appears to have been an encouraging 
level of compliance (79.2% to 87.5%) with an algorithm that required both a depth of 
understanding by the clinical staff and new systems to be put in place. However, a 
modelled scenario was more disappointing: by taking into account the failure to 
classify 14.5% of women as VS or VNS, it estimated that only 53% of women would 
be managed according to the VLM algorithm. However, such gaps in the care 
cascade are common and have been documented in many studies such as that of 
Bhardwaj et al. [22].  
The initial support given by the MSF team is likely to have contributed positively to 
these results; the study did not explore whether performance outcomes were 
sustained after the withdrawal of this support before the end of the study period. 
OUTCOMES OF IMPLEMENTATION OF THE VLM ALGORITHM 
Although there is no baseline for comparison, virological resuppression rates of up 
57.5% to 67.6% predelivery and 70.0% to 82.3% by three months postpartum 
suggest that, despite suboptimal adherence to the guidelines, the algorithm is at 
least partially achieving its purpose. The lower success rates calculated under 
different assumptions may appear disappointing; however, prior to the 
implementation of the algorithm, many of the 53 VNS women may not even have 
been identified, let alone managed appropriately. 
Given that routine data reports a PMTCT rate of 1.2% for Khayelitsha for the period 
of the study [17], it is remarkable that none of the babies tested at birth or at six 
weeks were HIV positive. Once again, the outcome may not have been as good as 
these results suggest. It is possible that the three infants who died within days of 
birth may have been infected in-utero. The possibility also exists that some of these 
results were false-negative, as in cases reported in the literature where negative 
PCR results were obtained in babies whose mothers were on ART, or were on 
prophylaxis themselves [23]. No results were found for five of the babies: some of 
these infants may have died before being tested. 
CHALLENGES IN IMPLEMENTATION OF THE VLM ALGORITHM 
In the process of data collection, several challenges were identified in the filing of 
patient folders and results, the accuracy of registers, clinical recordkeeping and 
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electronic monitoring systems, all of which are likely to have compromised the 
implementation of the VLM algorithm and resulted in gaps in care.. 
Several factors could have resulted in a failure to identify VNS women. Errors 
occurred in the classification of HIV positive women in the HCT register: some of 
these are a result of transcription errors, while others result from women deliberately 
not disclosing their HIV status and/or ART experience. These and further errors and 
oversights could have resulted in women not being entered into the VL/CD4 register 
or being incorrectly classified: such women would not have had a VL measured and 
thus not have been classified as VNS. As many results were not entered into the 
CD4/VL register, and use of the register ceased towards the end of the study period, 
it is likely that the system of timeous identification and recall of VNS women would 
have been more difficult.  
Suboptimal filing of patient folders and results and limited clinical record-keeping in 
MOU-retained records would have challenged the quality and continuity of care and 
compromised the implementation of elements of the algorithm such as repeating the 
measurement of VL, and changing ART regimen. It is hoped that clinical 
recordkeeping will improve with the introduction of stationery currently being 
designed at provincial level that will document both pregnancy and HIV information 
in an integrated facility-retained record; this will be captured into the electronic 
monitoring system. Innovative ways of improving access to, and filing and capturing 
of laboratory results are being piloted in some Khayelitsha facilities. 
Good communication and the sharing of clinical information is essential particularly 
when various components of care are provided at different sites. It was, however, 
impossible to share such information between the MOU, clinics and hospitals 
electronically due to the existence of different monitoring systems: in some cases, 
VLs had been repeated unnecessarily at another service, and there had been 
failures to change an ART regimen because clinicians were not aware of the results 
of a VL test performed at another site. While a search of the NHLS data base could 
have revealed this information, it would have been impractical do this routinely. 
From case histories, it was clear that implementation of the algorithm was 
sometimes compromised by situations in which the management of other patient 
conditions was more urgent: this was particularly evident in cases of women 
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delivering at the tertiary hospital where severe obstetric, medical and/or HIV-related 
complications took priority over management of a non-suppressed VL. 
 
LIMITATIONS OF STUDY 
The number of VNS women in the study was limited by errors in and omissions from 
the HCT and VL/CD4 registers and the exclusion of 12 ‘confessed’ defaulters who 
were identified late in the data collection process.. The small number of VNS women 
may have accounted for some of the variables not achieving significance as 
predictors of virological non-suppression. 
As this was not a formal prospective research cohort, it was necessary to use routine 
data sources. This proved challenging and time-consuming as data sought from 
registers, clinical records and electronic monitoring systems was often limited, 
incorrect, missing, or difficult to access, particularly where sites used different 
electronic monitoring systems. In some cases, it was necessary to rely to a 
considerable extent on NHLS results to construct a clinical case history. As a result, 
the data collected is incomplete and could contain inaccuracies. 
Given the challenges and time involved in data collection, it was decided to restrict 
the evaluation of the VLM algorithm to those sections that guide the antenatal 
management of those ART-experienced women, who were identified as being 
virologically non-suppressed at first antenatal visit.. The restricted data available on 
VS women limited many comparisons with VNS women. 
This study was conducted at one antenatal site only, in a peri-urban area of high HIV 
prevalence and good ART service coverage. MSF contributes to innovations and 
health systems strengthening in the ART clinic in the facility and at the study site, 
and provided additional support for the implementation of the algorithm. The results 
may thus not be generalisable to other contexts. 
CONCLUSIONS 
A high proportion (40%) of HIV positive pregnant women were ART-experienced at 
presentation for antenatal care. It is of concern that over 14% of these women were 
virologically non-suppressed at presentation for antenatal care as a result of poor 
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adherence to ART, the development of viral resistance, or having defaulted from 
ART entirely. It is imperative that clinicians and managers become informed of and 
understand the factors responsible for poor adherence and retention in care of 
women of reproductive age. The results of this study suggest a profile of women at 
high risk of poor adherence and/or defaulting: young women, women who have been 
on ART for more than a few years, women who move residence often or transfer 
care from one clinic to another, or who regularly migrate temporarily from one part of 
the country to another. Such women should be identified and received targeted and 
appropriate enhanced adherence support. 
Regardless of HIV status, all women of reproductive age should be regularly 
educated and counselled about HIV/ART and PMTCT. High prevalence of 
unplanned pregnancy in this context is well established, and therefore fertility 
intentions should be proactively discussed and provision of contraception integrated 
into ART care, as the backbone of PMTCT policy. There should be ongoing efforts to 
overcome denial of positive HIV status and to encourage disclosure. 
Given the many systems and human challenges faced in the implementation of the 
VLM algorithm, adherence to the guideline was encouraging, and the maternal VL 
resupression and infant PCR outcomes reassuring. However, there are several 
interventions at both local and provincial level that could improve the implementation 
of the VLM algorithm. These same interventions should positively impact on 
antenatal and ART care in general. 
It is likely that integration of antenatal and obstetric care would lead to improvements 
in adherence to the VLM guidelines. In fact, the Western Cape 2014 PMTCT 
guidelines [24] recommend that women receive integrated care (both antenatal and 
ART care) at the same facility, preferably from the same clinician. Women on ART 
could choose to receive this care at their ART site if it also offers antenatal care, or 
transfer their ART care to the MOU. For a variety of reasons, to date, few women 
have chosen this option. Obstacles to the implementation of this aspect of the 
guidelines should be identified and addressed. 
The adoption of a single networked electronic monitoring system would be ideal as it 
would allow for a more coordinated approach in clinical care.  
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The integrated HIV/obstetric stationery under development in the Western Cape 
should be fast-tracked; it should facilitate integrated care and improve clinical 
recordkeeping.  
Consideration should be given to the introduction of a register, preferably electronic, 
that could track the management of pregnant women on ART: such a longitudinal 
record could facilitate the identification of gaps in care, where women had not been 
managed according to guidelines, or had defaulted from care.  
A concerted effort should be made to improve systems for the filing of patient folders, 
the filing and electronic capture of laboratory results, the accurate completion of 
registers and improved clinical record-keeping.  
The introduction of new guidelines needs to be strongly supported by ongoing 
focused training, the design of systems, mentoring and monitoring by appropriate 
staff. 
Similar evaluations could be conducted of the implementation of more recent VLM 
guidelines. There is a need for research looking specifically at adherence and 
retention in care challenges of women of reproductive age initiated on ART, whether 
in the routine ART services or during pregnancy. This has become particularly 
important since the implementation of PMTCT Option B+ [25]. 
 
  
61 
 
REFERENCES  
1. World Health Organisation (2013) Consolidated guidelines on general HIV care and 
the use of antiretroviral drugs for treating and preventing HIV Infection. Available: 
www.int/hiv/pub/guidelines/arv2013. Accessed 1 April 2015. 
2. UNAIDS (2011) Countdown to Zero: Global plan towards the elimination of new HIV 
infection amongst children by 2015 and keeping their mothers alive. Available: 
http://hdl.handle.net/123456789/2. Accessed 15 March 2015. 
3. Kourtis A, Bulterys M (2010) Mother to Child Transmission of HIV: Pathogenesis, 
Mechanisms and Pathways. Clinical Perinatology 37:721-737.  
4. Ramkissoon A, Coovadia H (2014) Charting a path along the continuum of PMTCT of 
HIV-1 to elimination and finally to eradication. S Afr Med J 104(1):18-20. 
5. Newell M (2005) Current Issues in the Prevention of Mother-to-Child Transmission of 
HIV-1 Infection. Transactions of the Royal Society of Tropical Medicine and Hygiene. 
100:1-5. DOI 10.1016./j.trstmh.2005.05.012. 
6. Tucker J, Bien C, Easterbrook P, Doherty M, Penzzato M, Vitoria M, Peeling R (2014) 
Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected 
adults, adolescents, children and pregnant women: A systematic review. AIDS 28 
(Suppl 2):S151-S160.  
7. Boulle A, Ford N (2007) Scaling up antiretroviral therapy in developing countries: 
What are the benefits and challenges?  Sex Transm Infect 83:503-505.  
8. Ford N, Meintjies G, Pozniak A, Bygrave H, Hill N, Peter D, Davies M, Grinsztejn B, 
Calmy A et al. (2015) The future role of CD4 cell count for monitoring antiretroviral 
therapy.  The Lancet Infectious Diseases 15(1):241-247. 
9. Essajee S, Kumarasamy N (2014) Commentary: The monitoring of adults and 
children on antiretroviral therapy in the 2013 WHO Consolidated Guidelines. AIDS 
28(Suppl 2):S147-S149. 
10. Stevens W, Ford N (2014) Time to reduce CD4 monitoring of antiretroviral therapy in 
HIV-infected adults. S Afr Med J 104(8):559-560. 
11. British HIV Association (2014) British HIV Association Guidelines for the treatment of 
HIV-1-positive adults with anti-retroviral therapy. HIV Medicine 15(1):1-85. Available: 
DOI:10:1111/hiv.12119. Accessed 25 January 2015. 
12. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal 
Transmission (2014) Recommendations for use of antiretroviral drugs in pregnant 
HIV-1-infected women for maternal health and interventions to reduce perinatal HIV 
transmission in the United States. Available: 
http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. Accessed 17 March 2015. 
13. Department of Health Western Cape (2013) PMTCT Clinical Guidelines Update. 
Available: https://www.westerncape.gov.za/dept/Health/documents/guides/PMTCT. 
Accessed 9 January 2015.    
14.  Statistics South Africa (2012) Census 2011. Available: 
www.statssa.gov.za/census/census_2011/census.../Census_2011_Statistica. 
Accessed 30 April 2015. 
15. Provincial government of the Western Cape (2013) Antenatal HIV prevalence survey. 
2012.  
16. Myer L, Phillips T, Zerbe A, Hsiao M., McIntyre J, Bekker L-G & Abrams E (2014)  
Detectable Viraemia among pregnant women on antiretroviral therapy initiating 
62 
 
antenatal care: Implications for the prevention of mother-to-child transmission.  Poster 
874 at 21st Conf Retrovir Oppor Infect. 3-6 March 2014. Boston. 
17. Routine data 
18. Columbini M, Stockl H, Watts C, Zimmerman C, Agamasu E, Mayhew H (2014) 
Factors influencing adherence for short-course ARV prophylaxis for preventing 
mother-to-child transmission of HIV in sub-Saharan Africa: A review and lessons for 
future elimination. AIDS Care 26(7):914-926.  
19. Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A (2013) Barriers and 
facilitating factors to the uptake of antiretroviral drugs for the prevention of mother-to-
child transmission of HIV in sub-Saharan Africa: A systematic review. Journal of the 
International AIDS Society 16:18588. 
20. Claborn K, Meier E, Miller M, Leffingwell T (2015) A systematic review of treatment 
fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health 
Med 20(3):255-265. 
21. Augustine E 2015. Personal communication. 
22.  Bhardwaj S, Barron P, Pillay Y, Treger-Slavin L, Robinson P, Goga A, Sherman G 
(2014) Elimination of mother-to-child transmission of HIV in South Africa: Rapid scale-
up using quality improvement. S Afr Med J 104(3):239-243. 
23. Haeri Mazenderani A, Du Plessis N, Thomas W, Venter E, Avenant T (2014) Loss of 
detectability and indeterminate results: Challenges facing HIV infant diagnosis in 
South Africa’s expanding ART programme. S Afr Med J 104(8):574-577. 
24. Department of Health Western Cape (2014) PMTCT Clinical Guidelines Update 
Available: https://www.westerncape.gov.za/dept/Health/documents/guides/PMTCT. 
Accessed 3 April 2015. 
25. Tenthani L,  Haas A,  Tweya H,  Jahn A, van Oosterhout J, Chimbwandiri F, Chirwa Z, 
Ng’ambi W et al (2014) Retention in care under universal antiretroviral therapy for 
HIV-infected pregnant and breastfeeding women (‘Option B+’) in Malawi. AIDS 
28:589-598. 
 
63 
 
TABLES AND FIGURES 
 
 
 
 
 
Virologically 
supressed, n=387, 
(88.0%) 
Virologically 
non-
supressed,            
n=53 P-value Total, n (%)                                                                  
Test 
Type
387, (88.0) 53, (12.0)
Age (years), mean (SD) 32 (4.8) 31 (5.4) 0.17 1
Age (years), n (%) 364, (94.1) 53 (12.0)
15-24 19 (5.2) 7, (13.2) 0.20 26 (9.2) 9.2 2
25-29 85 (23.4) 15, (28.3) 100 (25.8) 25.8
30-34 138 (37.9) 15 (28.3) 153 (33.1) 33.1
35-39 95 (26.1) 14, (26.4) 109 (26.3) 26.3
≥ 40 27 (7.4) 2, (3.8) 29 (5.6) 5.6
31 (18-50) 37 (19-63) 3
Duration on ART at booking (months), n (%) 318, (82.2) 53, (100) 0.23 371, (84.3) 2
≤11 51, (16.0) 8, (15.1) 0.40 59 15.6
12-23 69, (21.7) 9, (17.0) 78 19.3
24-35 64, (20.1) 8, (15.1) 72 17.6
36-59 79, (24.8) 13, (24.5) 92 24.7
≥60 55, (17.3) 15, (28.3) 70 22.8
ART regimen at 1st antenatal visit, n (%) 320, (82.7) 53, (100.0) 373 84.8
1st line 298, (93.1) 46, (86.8) 0.07 344 90.0 2
2nd line 22 (6.9) 7, (13.2) 29 10.0
319, (82.4) 53, (100.0) 372 89.2
Closest clinic 185,(58.0) 21, (39.6) 0.06 206 55.4 2
Other Khayelitsha sites 86, (27.0) 20, (37.7) 106 28.5
Other sites 48 (15.0) 12, (22.6) 60 16.1
SD - Standard Deviation; IQR - Inter Quartile Range; Test Type: 1. 2 Sample t-test; 2. Chi-square test; 3. Wilcoxon Rank-Sum test
Most recent  ART clinic, n (%)
Characteristics, n (%)
Duration on ART at booking (months), median (IQR
Table 1:  Characteritics of virologically suppressed and virologically non-suppressed antiretroviral-experienced pregnant women (n=440)
Odds ratio p-value 95% CI
Unadjusted/adjusted Unadjusted/adjusted Unadjusted/adjusted
Regimen, n (%) 320 (82.7) 53 (100.0)
1st line  (reference)
2nd line 2.3/2.3 0.08/0.08 0.9-5.7/0.9-6.2
Clinic, n (%) 319 (82.4) 53 (100.0)
closest clinic  (reference)
all other clinis 2.0/2.2 0.02/0.02 1.1-3.7/1.2- 4.3
Duration on ART (years), n (%) 318 (82.2) 53 (100.0)
< 4 (reference)
≥4 1.8/2.1 0.05/0.04 1.0-3.3/1.1-4.3
Age (years), n (%) 364 (94.1) 53 (100.0)
< 25  (reference)
25-29 0.5/0.5 0.13/0.30 0.2-1.3/0.2-1.3
≥35 0.3/0.3 0.02/0.05 0.1-0.9/0.01-1
Constant 0.2 0.01 0.1-0.7
Table 2: Logistic regression model of predictors of being virologically non-suppressed 
Variable
Virologically non-
supressed (n=53)
Virologically 
supressed(n=387)
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Viral Load CD4 < 100   CD4=100-199 CD4=200-349  CD4=350-499   CD4 ≥ 500   Total N
Viral Load (log), n (%) 8 (16.3) 11( 22.5) 18 (36.7) 7 (14.3) 5 (10.2) 49 (100)
< log 3 1 (8.3) 3 (25.0) 3 (25.0) 2 (16.7) 3 (25.0) 12 (24.5)
log3  <log4 2 (10.5) 3 (15.8) 9 (47.4) 3 (15.8) 2 (10.5) 19 (38.8)
log4 < log 5 0 4 (36.3) 5 (45.5) 2 (18.2) 0 11 (22.4)
≥ log5 5 (71.4) 1 (14.3) 1 (14.3) 0 0 7 (14.3)
Table 3b: CD4 count compared to booking viral load in virologically non-suppressed antiretroviral-experienced 
pregnant women (N=49)
Virologically non-suppressed 
(n=53)
252 (170-338)
49 (92.5)
<100 8 (16.3)
100-199 11 (22.4)
200-350 18 (36.7)
350-499 7 (14.3)
≥500 5 (10.2)
3929 (898-49119)
Booking Viral Load, n (%) 53 (100)
401 - 999 14 (26.4)
Log 3 < 4 20 (37.7)
Log 4 < 5 12 (22.6)
Log 5 < 6 7 (13.2)
Viral Load (value), Median (IQR)
Table 3a: Clinical characteristics of virologically non-suppressed 
antiretroviral-experienced pregnant women (n=53)
Characteristic
CD4 (value), Median (IQR) 
Last CD4 (value) before first antenatal visit, n (%)
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Characteristic VNS women (n=53)
19 (16-27)
49 (92.5)
≤12 weeks 7 (14.3)
13 –20 weeks  21 (42.9)
21-28 weeks  14 (28.6)
29 - 32 weeks 4 (8.2)
>32 weeks  3 (6.1)
2.6 (1.2)
49 (92.5)
G1 11 (22.4)
G2 13 (26.5)
G3 11 (22.4)
G4  11 (22.4)
G5 3 (6.1)
Pregnancy outcomes 53(100)
Confirmed miscarriage 3 (5.6)
Probable miscarriage1 1 (1.9)
Probable TOP2 1 (1.9)
Live deliveries 48(90.6)
45 (84.9)
Study site MOU 15 (33.2)
Khayelitsha District Hospital  13 (28.9)
Tygerberg hospital  15 (33.3)
Other 2 (4.4)
Delivery outcome, n (%) 48 (90.6)
Alive at 6 weeks 45 (85.0)
Early neonatal deaths3 3 (5.6)
Foetal abnormalities on ultrasound
30 yr women offered TOP for Trisomy 21
43 yr women suspected Trisomy 21,  neonatal death
35 yr women : foetus with major cardiac abnormalities
39 year women; unspecified abnormalies; 2 previous IUDs and NND
* NND : neonatal death
* IUD : intrauterine death
* TOP : termination of pregnancy
1 No birth record
2 Offered TOP for Trisomy 21 foetus
3 Infant with Serratia sepsis
Infant delivered by emergency C/S; mother with postpartum sepsis, unconfirmed maternal death
Infant with Trisomy 21 on Ultrasound
Table 4: Obstetric characteristics of virologically non-suppressed antiretroviral-
experienced pregnant women (n=53)
Gestational age at 1st antenatal visit (weeks), n, (%)
Gestational age at 1st antenatal visit (weeks), median (IQR)
Gravidity, n (%)
Delivery site, n (%)
Gravidity, mean (SD)
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Folders Audited (N=37)
Characteristic, n (%)
Maternal case records in folder 10 (27.0)
VL result hard copy in folder 12 (32.4)
VL result in clinical notes 13 (35.1)
No VL result in folder 15 (40.5)
Record in folder of reasons for poor adherence 8 (21.6)
Record in folder of receiving adjerence support 15 (40.5)
Formal letter for transfer of ART care to MOU 1 (2.7)
Transfer of ART care to MOU assumed from clinical notes 12 (32.4)
Table 5: Audit of clinical record-keeping supporting the VLM algorithm 
*VLM-Viral Load Monitoring; VL-Viral Load; ART-Anti-retroviral; MOU-Maternal & Obstetric Unit
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Figure 1: Cohort of HIV positive pregnant women (n=1412)
1412 HIV positive pregnant 
women
848 ART-naïve (60%)
564 ART-experienced 
women (40%)
82 No VL results  (14.5%)
482
ART-experienced 
women with VL results 
(85.5%)
414
Women with VL 
results VS (85.9%) 68
 Women with VL 
results VNS (14.1%)
27 Excluded1 (6.5%) 15 Excluded2 (22.1%)
387
 Included in analysis 
(93.5% of VS 
women)
53 Included in analysis 
(77.9% of VNS women) 
* VS : virologically suppressed
* VNS : virologically non-supressed
1. Women identified as being VS from sources other than the VL/CD4 register
2. Defaulters (12) and women identified as being VNS (3) from sources other than the VL/CD4 register
Figure 2: Adherence characteristics of antiretroviral-experienced pregnant women 
who are virologically non-suppressed (n=53) 
Attended> 1 cl inic 22(41.4%) 
Attended clinic outside Khayelitsha 22(41.4%) 
Previously defau lted and resta rted ART 20 {37.8%) 
Switch to 2nd li ne indicated in past but did not happen 
No record of postpartum attendance at ART clinic found 22 (41.5%) 
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FIGURE 3: VIROLOGICAL OUTCOMES IN VIROLOGICALLY NON-SUPPRESSED ANTI-
RETROVIRAL EXPERIENCED PREGNANT WOMEN 
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